glp-1 cardiovascular outcomes news today Agonists in Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies Comparative effectiveness of GLP-1 receptor

Hence, SCFAs also have beneficial effects on peripheral tissues, controlling substrate metabolism and optimizing systemic insulin sensitivity

All records are clean

This class of drugs have been around for 20+ years so we do know the most common side effects are GI in nature (nausea, vomiting, constipation and diarrhea), Kaplan said

These include: Pre-existing constipation or slow transit constipation Inadequate dietary fibre intake Insufficient fluid consumption Reduced physical activity levels Concurrent medications with constipating effects (such as opioids, certain antidepressants, or iron supplements) Older age , where baseline colonic motility may already be reduced The severity of constipation often correlates with the dose of medication and may be more pronounced during dose escalation phases

Secondary Benefits GLP-1 drugs also appear to have some extra benefits

The Basis for Weekly Insulin Therapy: Evolving Evidence With Insulin Icodec and Insulin Efsitora Alfa